|
1
|
Lin YT, Huang AC, Kuo CL, Yang JS, Lan YH,
Yu CC, Huang WW and Chung JG: Induction of cell cycle arrest and
apoptosis in human osteosarcoma U-2 OS cells by Solanum lyratum
extracts. Nutr Cancer. 65:469–479. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liang CZ, Zhang X, Li H, Tao YQ, Tao LJ,
Yang ZR, Zhou XP, Shi ZL and Tao HM: Gallic acid induces the
apoptosis of human osteosarcoma cells in vitro and in vivo via the
regulation of mitogen-activated protein kinase pathways. Cancer
Biother Radiopharm. 27:701–710. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cho HJ, Lee TS, Park JB, Park KK, Choe JY,
Sin DI, Park YY, Moon YS, Lee KG, Yeo JH, et al: Disulfiram
suppresses invasive ability of osteosarcoma cells via the
inhibition of MMP-2 and MMP-9 expression. J Biochem Mol Biol.
40:1069–1076. 2007.PubMed/NCBI
|
|
4
|
Marina N, Gebhardt M, Teot L and Gorlick
R: Biology and therapeutic advances for pediatric osteosarcoma.
Oncologist. 9:422–441. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chou AJ, Geller DS and Gorlick R: Therapy
for osteosarcoma: where do we go from here? Paediatr Drugs.
10:315–327. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chou AJ and Gorlick R: Chemotherapy
resistance in osteosarcoma: current challenges and future
directions. Expert Rev Anticancer Ther. 6:1075–1085. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dieudonné FX, Marion A, Haÿ E, Marie PJ
and Modrowski D: High Wnt signaling represses the proapoptotic
proteoglycan syndecan-2 in osteosarcoma cells. Cancer Res.
70:5399–5408. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang ZY, Mei J, Gao YS, Ni M and Yao B:
Primary tumorectomy promotes angiogenesis and pulmonary metastasis
in osteosarcoma-bearing nude mice. Acta Cir Bras. 28:190–194. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Agarwal R and Kaye SB: Ovarian cancer:
strategies for overcoming resistance to chemotherapy. Nat Rev
Cancer. 3:502–516. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Glavinas H, Krajcsi P, Cserepes J and
Sarkadi B: The role of ABC transporters in drug resistance,
metabolism and toxicity. Curr Drug Deliv. 1:27–42. 2004. View Article : Google Scholar
|
|
11
|
Gottesman MM, Fojo T and Bates SE:
Multidrug resistance in cancer: role of ATP-dependent transporters.
Nat Rev Cancer. 2:48–58. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ozben T: Mechanisms and strategies to
overcome multiple drug resistance in cancer. FEBS Lett.
580:2903–2909. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Higgins CF: Multiple molecular mechanisms
for multidrug resistance transporters. Nature. 446:749–757. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bodey B, Taylor CR, Siegel SE and Kaiser
HE: Immunocytochemical observation of multidrug resistance (MDR)
p170 glycoprotein expression in human osteosarcoma cells. The
clinical significance of MDR protein overexpression. Anticancer
Res. 15:2461–2468. 1995.PubMed/NCBI
|
|
15
|
Chano T, Mori K, Scotlandi K, Benini S,
Lapucci C, Manara MC, Serra M, Picci P, Okabe H and Baldini N:
Differentially expressed genes in multidrug resistant variants of
U-2 OS human osteosarcoma cells. Oncol Rep. 11:1257–1263.
2004.PubMed/NCBI
|
|
16
|
Okada T, Tanaka K, Nakatani F, Sakimura R,
Matsunobu T, Li X, Hanada M, Nakamura T, Oda Y, Tsuneyoshi M and
Iwamoto Y: Involvement of P-glycoprotein and MRP1 in resistance to
cyclic tetrapeptide subfamily of histone deacetylase inhibitors in
the drug-resistant osteosarcoma and Ewing's sarcoma cells. Int J
Cancer. 118:90–97. 2006. View Article : Google Scholar
|
|
17
|
Susa M, Iyer AK, Ryu K, Choy E, Hornicek
FJ, Mankin H, Milane L, Amiji MM and Duan Z: Inhibition of ABCB1
(MDR1) expression by an siRNA nanoparticulate delivery system to
overcome drug resistance in osteosarcoma. PLoS One. 5:e107642010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pluchino KM, Hall MD, Goldsborough AS,
Callaghan R and Gottesman MM: Collateral sensitivity as a strategy
against cancer multidrug resistance. Drug Resist Updat. 15:98–105.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shukla S, Ohnuma S and Ambudkar SV:
Improving cancer chemotherapy with modulators of ABC drug
transporters. Curr Drug Targets. 12:621–630. 2011. View Article : Google Scholar
|
|
20
|
Anuchapreeda S, Leechanachai P, Smith MM,
Ambudkar SV and Limtrakul PN: Modulation of P-glycoprotein
expression and function by curcumin in multidrug-resistant human KB
cells. Biochem Pharmacol. 64:573–582. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cocker HA, Tiffin N, Pritchard-Jones K,
Pinkerton CR and Kelland LR: In vitro prevention of the emergence
of multidrug resistance in a pediatric rhabdomyosarcoma cell line.
Clin Cancer Res. 7:3193–3198. 2001.PubMed/NCBI
|
|
22
|
Yen WC and Lamph WW: The selective
retinoid X receptor agonist bexarotene (LGD1069, Targretin)
prevents and overcomes multidrug resistance in advanced breast
carcinoma. Mol Cancer Ther. 4:824–834. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sharma AK, Zhang L, Li S, Kelly DL,
Alakhov VY, Batrakova EV and Kabanov AV: Prevention of MDR
development in leukemia cells by micelle-forming polymeric
surfactant. J Control Release. 131:220–227. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Batrakova EV, Kelly DL, Li S, Li Y, Yang
Z, Xiao L, Alakhova DY, Sherman S, Alakhov VY and Kabanov AV:
Alteration of genomic responses to doxorubicin and prevention of
MDR in breast cancer cells by a polymer excipient: pluronic P85.
Mol Pharm. 3:113–123. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sarisozen C, Vural I, Levchenko T, Hincal
AA and Torchilin VP: PEG-PE-based micelles co-loaded with
paclitaxel and cyclosporine A or loaded with paclitaxel and
targeted by anticancer antibody overcome drug resistance in cancer
cells. Drug Delivery. 19:169–176. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kolitz JE, George SL, Marcucci G, Vij R,
Powell BL, Allen SL, DeAngelo DJ, Shea TC, Stock W, Baer MR, et al:
P-glycoprotein inhibition using valspodar (PSC-833) does not
improve outcomes for patients younger than age 60 years with newly
diagnosed acute myeloid leukemia: cancer and leukemia group B study
19808. Blood. 116:1413–1421. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gandhi L, Harding MW, Neubauer M, Langer
CJ, Moore M, Ross HJ, Johnson BE and Lynch TJ: A phase II study of
the safety and efficacy of the multidrug resistance inhibitor
VX-710 combined with doxorubicin and vincristine in patients with
recurrent small cell lung cancer. Cancer. 109:924–932. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
O'Brien MM, Lacayo NJ, Lum BL, Kshirsagar
S, Buck S, Ravindranath Y, Bernstein M, Weinstein H, Chang MN,
Arceci RJ, et al: Phase I study of valspodar (PSC-833) with
mitoxantrone and etoposide in refractory and relapsed pediatric
acute leukemia: a report from the Children's Oncology Group.
Pediatr Blood Cancer. 54:694–702. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kelly RJ, Draper D, Chen CC, Robey RW,
Figg WD, Piekarz RL, Chen X, Gardner ER, Balis FM, Venkatesan AM,
et al: A pharmaco-dynamic study of docetaxel in combination with
the P-glycoprotein antagonist tariquidar (XR9576) in patients with
lung, ovarian, and cervical cancer. Clin Cancer Res. 17:569–580.
2011. View Article : Google Scholar
|
|
30
|
Schiff PL Jr: Bisbenzylisoquinoline
alkaloids. J Nat Prod. 50:529–599. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jang BC, Lim KJ, Paik JH, Cho JW, Baek WK,
Suh MH, Park JB, Kwon TK, Park JW, Kim SP, et al:
Tetrandrine-induced apoptosis is mediated by activation of caspases
and PKC-delta in U937 cells. Biochem Pharmacol. 67:1819–1829. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Meng LH, Zhang H, Hayward L, Takemura H,
Shao RG and Pommier Y: Tetrandrine induces early G1 arrest in human
colon carcinoma cells by down-regulating the activity and inducing
the degradation of G1-S-specific cyclin-dependent kinases and by
inducing p53 and p21Cip1. Cancer Res. 64:9086–9092. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu C, Gong K, Mao X and Li WL:
Tetrandrine induces apoptosis by activating reactive oxygen species
and repressing Akt activity in human hepatocellular carcinoma. Int
J Cancer. 129:1519–1531. 2011. View Article : Google Scholar
|
|
34
|
Wan J1 Liu T, Mei L, Li J, Gong K, Yu C
and Li W: Synergistic antitumour activity of sorafenib in
combination with tetrandrine is mediated by reactive oxygen species
(ROS)/Akt signaling. Br J Cancer. 109:342–350. 2013. View Article : Google Scholar
|
|
35
|
Ao Z and Xia W: Reversal of daunorubicin
resistance by tetrandrine in leukemic cells. Zhonghua Xue Ye Xue Za
Zhi. 16:235–238. 1995.
|
|
36
|
Wei N, Sun H, Wang F and Liu G: H1, a
novel derivative of tetrandrine reverse P-glycoprotein-mediated
multidrug resistance by inhibiting transport function and
expression of P-glycoprotein. Cancer Chemother Pharmacol.
67:1017–1025. 2011. View Article : Google Scholar
|
|
37
|
Shen H, Xu W, Chen Q, Wu Z, Tang H and
Wang F: Tetrandrine prevents acquired drug resistance of K562 cells
through inhibition of mdr1 gene transcription. J Cancer Res Clin
Oncol. 136:659–665. 2010. View Article : Google Scholar
|
|
38
|
Yang X, Yang P, Shen J, Osaka E, Choy E,
Cote G, Harmon D, Zhang Z, Mankin H, Hornicek FJ and Duan Z:
Prevention of multidrug resistance (MDR) in osteosarcoma by
NSC23925. Br J Cancer. 110:2896–2904. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang L, Meng Q, Wang C, Liu Q, Peng J, Huo
X, Sun H, Ma X and Liu K: Dioscin restores the activity of the
anticancer agent adriamycin in multidrug-resistant human leukemia
K562/adriamycin cells by down-regulating MDR1 via a mechanism
involving NF-κB signaling inhibition. J Nat Prod. 76:909–914. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chiu LY, Ko JL, Lee YJ, Yang TY, Tee YT
and Sheu GT: L-type calcium channel blockers reverse docetaxel and
vincristine-induced multidrug resistance independent of ABCB1
expression in human lung cancer cell lines. Toxicol Lett.
192:408–418. 2010. View Article : Google Scholar
|
|
41
|
Sun J, Yeung CA, Co NN, Tsang TY, Yau E,
Luo K, Wu P, Wa JC, Fung KP, Kwok TT and Liu F: Clitocine reversal
of P-glycoprotein associated multi-drug resistance through
down-regulation of transcription factor NF-κB in R-HepG2 cell line.
PLoS One. 7:e407202012. View Article : Google Scholar
|
|
42
|
Kuo MT, Liu Z, Wei Y, Lin-Lee YC, Tatebe
S, Mills GB and Unate H: Induction of human MDR1 gene expression by
2-acetylaminofluorene is mediated by effectors of the
phosphoinositide 3-kinase pathway that activate NF-kappaB
signaling. Oncogene. 21:1945–1954. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Leonard GD, Fojo T and Bates SE: The role
of ABC transporters in clinical practice. Oncologist. 8:411–424.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Susa M, Choy E, Yang C, Schwab J, Mankin
H, Hornicek F and Duan Z: Multidrug resistance reversal agent,
NSC77037, identified with a cell-based screening assay. J Biomol
Screen. 15:287–296. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Suto R, Abe Y, Nakamura M, Ohnishi Y,
Yoshimura M, Lee YH, Imanishi T, Yamazaki H, Kijima H, Tokunaga T,
et al: Multidrug resistance mediated by overexpression of
P-glycoprotein in human osteosarcoma in vivo. Int J Oncol.
12:287–291. 1998.PubMed/NCBI
|
|
46
|
Szakács G, Paterson JK, Ludwig JA,
Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in
cancer. Nat Rev Drug Discov. 5:219–234. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhang H, Li YY and Wu XZ: Effect of
Tetrandrine on LPS-induced NF-kappaB activation in isolated
pancreatic acinar cells of rat. World J Gastroenterol.
12:4232–4236. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ho LJ, Juan TY, Chao P, Wu WL, Chang DM,
Chang SY and Lai JH: Plant alkaloid tetrandrine downregulates
IkappaBalpha kinases-IkappaBalpha-NF-kappaB signaling pathway in
human peripheral blood T cell. Br J Pharmacol. 143:919–927. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Bentires-Alj M, Barbu V, Fillet M, Chariot
A, Relic B, Jacobs N, Gielen J, Merville MP and Bours V: NF-kappaB
transcription factor induces drug resistance through MDR1
expression in cancer cells. Oncogene. 22:90–97. 2003. View Article : Google Scholar : PubMed/NCBI
|
